5 References

  • 1
    Topol, E. J., Intensive statin therapy–a sea change in cardiovascular prevention. New Engl. J. Med. 2004, 350, 15621564.
  • 2
    Henke, A. C., Jensen, C. S., Cohen, M. B., Cytologic diagnosis of adenocarcinoma in biliary and pancreatic duct brushings. Adv. Anat. Pathol. 2002, 9, 301308.
  • 3
    Sacks, F. M., Pfeffer, M. A., Moye, L. A., Rouleau, J. L. et al., The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. New Engl. J. Med. 1996, 335, 10011009.
  • 4
    Shepherd, J., Cobbe, S. M., Ford, I., Isles, C. G. et al., Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. New Engl. J. Med. 1995, 333, 13011307.
  • 5
    Olsson, A. G., [The last round about statins: there is the fact that 80 mg simvastatin daily results in high risk of myopathy]. Lakartidningen 2009, 106, 27832784.
  • 6
    Rosenson, R. S., Current overview of statin-induced myopathy. Am. J. Med. 2004, 116, 408416.
  • 7
    Sathasivam, S., Statin induced myotoxicity. Eur. J. Intern. Med. 2012, 23, 317324.
  • 8
    Parker, N., The Garry David case. Aust. NZ J. Psychiat. 1991, 25, 371374.
  • 9
    Marcoff, L., Thompson, P. D., The role of coenzyme Q10 in statin-associated myopathy: a systematic review. J. Am. Coll. Cardiol. 2007, 49, 22312237.
  • 10
    Sirvent, P., Mercier, J., Lacampagne, A., New insights into mechanisms of statin-associated myotoxicity. Curr. Opin. Pharmacol. 2008, 8, 333338.
  • 11
    Bjornsson, E., Jacobsen, E. I., Kalaitzakis, E., Hepatotoxicity associated with statins: reports of idiosyncratic liver injury post-marketing. J. Hepatol. 2012, 56, 374380.
  • 12
    Clarke, A. T., Mills, P. R., Atorvastatin associated liver disease. Dig. Liver Dis. 2006, 38, 772777.
  • 13
    Davidson, M. H., Combination therapy for dyslipidemia: safety and regulatory considerations. Am. J. Cardiol. 2002, 90, 50K60K.
  • 14
    Lata, S., Chudy, B., Acute cholestatic hepatitis caused by simvastatine in a 67-year-old patient. Przeglad Lekarski 2006, 63 Suppl 7, 9798.
  • 15
    Van Summeren, A., Renes, J., van Delft, J. H., Kleinjans, J. C., Mariman, E. C., Proteomics in the search for mechanisms and biomarkers of drug-induced hepatotoxicity. Toxicol. In Vitro 2012, 26, 373385.
  • 16
    Wetmore, B. A., Merrick, B. A., Toxicoproteomics: proteomics applied to toxicology and pathology. Toxicol. Pathol. 2004, 32, 619642.
  • 17
    Barrier, M., Mirkes, P. E., Proteomics in developmental toxicology. Reprod. Toxicol. 2005, 19, 291304.
  • 18
    Donato, P., Cacciola, F., Sommella, E., Fanali, C. et al., Online comprehensive RPLC x RPLC with mass spectrometry detection for the analysis of proteome samples. Anal. Chem. 2011, 83, 24852491.
  • 19
    Com, E., Boitier, E., Marchandeau, J. P., Brandenburg, A. et al., Integrated transcriptomic and proteomic evaluation of gentamicin nephrotoxicity in rats. Toxicol. Appl. Pharmacol. 2012, 258, 124133.
  • 20
    Martyniuk, C. J., Kroll, K. J., Doperalski, N. J., Barber, D. S., Denslow, N. D., Genomic and proteomic responses to environmentally relevant exposures to dieldrin: indicators of neurodegeneration? Toxicol. Sci. 2010, 117, 190199.
  • 21
    Klinefelter, G. R., Strader, L. F., Suarez, J. D., Roberts, N. L., Bromochloroacetic acid exerts qualitative effects on rat sperm: implications for a novel biomarker. Toxicol. Sci. 2002, 68, 164173.
  • 22
    Ortiz, P. A., Bruno, M. E., Moore, T., Nesnow, S. et al., Proteomic analysis of propiconazole responses in mouse liver: comparison of genomic and proteomic profiles. J. Proteome Res. 2010, 9, 12681278.
  • 23
    Cho, Y. E., Singh, T. S., Lee, H. C., Moon, P. G. et al., In-depth identification of pathways related to cisplatin-induced hepatotoxicity through an integrative method based on an informatics-assisted label-free protein quantitation and microarray gene expression approach. Mol. Cell. Proteome. 2012, 11, M111 010884.
  • 24
    Groneberg, D. A., Grosse-Siestrup, C., Fischer, A., In vitro models to study hepatotoxicity. Toxicol. Pathol. 2002, 30, 394399.
  • 25
    Gebhardt, R., Hengstler, J. G., Muller, D., Glockner, R. et al., New hepatocyte in vitro systems for drug metabolism: metabolic capacity and recommendations for application in basic research and drug development, standard operation procedures. Drug Metab. Rev. 2003, 35, 145213.
  • 26
    Han, C. L., Chen, J. S., Chan, E. C., Wu, C. P. et al., An informatics-assisted label-free approach for personalized tissue membrane proteomics: case study on colorectal cancer. Mol. Cell. Proteome. 2011, 10, M110 003087.
  • 27
    Tsou, C. C., Tsai, C. F., Tsui, Y. H., Sudhir, P. R. et al., IDEAL-Q, an automated tool for label-free quantitation analysis using an efficient peptide alignment approach and spectral data validation. Mol. Cell. Proteome. 2010, 9, 131144.
  • 28
    Wang, Y. T., Tsai, C. F., Hong, T. C., Tsou, C. C. et al., An informatics-assisted label-free quantitation strategy that depicts phosphoproteomic profiles in lung cancer cell invasion. J. Proteome Res. 2010, 9, 55825597.
  • 29
    Figliomeni, M. L., Abdel-Rahman, M. S., Ethanol does not increase the hepatotoxicity of cocaine in primary rat hepatocyte culture. Toxicology 1998, 129, 125135.
  • 30
    Han, C. L., Chien, C. W., Chen, W. C., Chen, Y. R. et al., A multiplexed quantitative strategy for membrane proteomics: opportunities for mining therapeutic targets for autosomal dominant polycystic kidney disease. Mol. Cell. Proteome. 2008, 7, 19831997.
  • 31
    Moon, P. G., Lee, J. E., You, S., Kim, T. K. et al., Proteomic analysis of urinary exosomes from patients of early IgA nephropathy and thin basement membrane nephropathy. Proteomics 2011, 11, 24592475.
  • 32
    Rowe, C., Goldring, C. E., Kitteringham, N. R., Jenkins, R. E. et al., Network analysis of primary hepatocyte dedifferentiation using a shotgun proteomics approach. J. Proteome Res. 2010, 9, 26582668.
  • 33
    Lee, M. H., Hong, I., Kim, M., Lee, B. H. et al., Gene expression profiles of murine fatty liver induced by the administration of valproic acid. Toxicol. Appl. Pharmacol. 2007, 220, 4559.
  • 34
    Bolstad, B. M., Irizarry, R. A., Astrand, M., Speed, T. P., A comparison of normalization methods for high density oligonucleotide array data based on variance and bias. Bioinformatics 2003, 19, 185193.
  • 35
    Huber, W., von Heydebreck, A., Sultmann, H., Poustka, A., Vingron, M., Variance stabilization applied to microarray data calibration and to the quantification of differential expression. Bioinformatics 2002, 18 Suppl 1, S96S104.
  • 36
    Livak, K. J., Schmittgen, T. D., Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods 2001, 25, 402408.
  • 37
    Mullen, P. J., Luscher, B., Scharnagl, H., Krahenbuhl, S., Brecht, K., Effect of simvastatin on cholesterol metabolism in C2C12 myotubes and HepG2 cells, and consequences for statin-induced myopathy. Biochem. Pharmacol. 2010, 79, 12001209.
  • 38
    Tavintharan, S., Ong, C. N., Jeyaseelan, K., Sivakumar, M. et al., Reduced mitochondrial coenzyme Q10 levels in HepG2 cells treated with high-dose simvastatin: a possible role in statin-induced hepatotoxicity? Toxicol. Appl. Pharmacol. 2007, 223, 173179.
  • 39
    Waters, K. M., Pounds, J. G., Thrall, B. D., Data merging for integrated microarray and proteomic analysis. Brief. Funct. Genomic Proteomic 2006, 5, 261272.
  • 40
    Chen, G., Gharib, T. G., Huang, C. C., Thomas, D. G. et al., Proteomic analysis of lung adenocarcinoma: identification of a highly expressed set of proteins in tumors. Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res. 2002, 8, 22982305.
  • 41
    Wood, Z. A., Poole, L. B., Karplus, P. A., Peroxiredoxin evolution and the regulation of hydrogen peroxide signaling. Science 2003, 300, 650653.
  • 42
    Immenschuh, S., Fahimi, H. D., Baumgart-Vogt, E., Complementary regulation of heme oxygenase-1 and peroxiredoxin I gene expression by oxidative stress in the liver. Cell Mol. Biol. (Noisy-le-grand) 2005, 51, 471477.
  • 43
    Yamamoto, T., Kikkawa, R., Yamada, H., Horii, I., Identification of oxidative stress-related proteins for predictive screening of hepatotoxicity using a proteomic approach. J. Toxicol. Sci. 2005, 30, 213227.
  • 44
    Bae, S. H., Sung, S. H., Lee, H. E., Kang, H. T. et al., Peroxiredoxin III and sulfiredoxin together protect mice from pyrazole-induced oxidative liver injury. Antioxid. Redox Sign. 2012, 17, 13511361.
  • 45
    Zelko, I. N., Mariani, T. J., Folz, R. J., Superoxide dismutase multigene family: a comparison of the CuZn-SOD (SOD1), Mn-SOD (SOD2), and EC-SOD (SOD3) gene structures, evolution, and expression. Free Radical Biol. Med. 2002, 33, 337349.
  • 46
    Zhu, J. H., McClung, J. P., Zhang, X., Aregullin, M. et al., Comparative impacts of knockouts of two antioxidant enzymes on acetaminophen-induced hepatotoxicity in mice. Exp. Biol. Med. (Maywood) 2009, 234, 14771483.
  • 47
    Yoshikawa, Y., Morita, M., Hosomi, H., Tsuneyama, K. et al., Knockdown of superoxide dismutase 2 enhances acetaminophen-induced hepatotoxicity in rat. Toxicology 2009, 264, 8995.
  • 48
    Lu, X., Enantioselective effect of bifenthrin on antioxidant enzyme gene expression and stress protein response in PC12 cells. J. Appl. Toxicol. 2012, doi: 10.1002/jat.1774.
  • 49
    Gum, S. I., Jo, S. J., Ahn, S. H., Kim, S. G. et al., The potent protective effect of wild ginseng (Panax ginseng C.A. Meyer) against benzo[alpha]pyrene-induced toxicity through metabolic regulation of CYP1A1 and GSTs. J. Ethnopharmacol. 2007, 112, 568576.
  • 50
    Henderson, C. J., Wolf, C. R., Kitteringham, N., Powell, H. et al., Increased resistance to acetaminophen hepatotoxicity in mice lacking glutathione S-transferase Pi. Proc. Natl. Acad. Sci. USA 2000, 97, 1274112745.
  • 51
    Gardner, C. R., Mishin, V., Laskin, J. D., Laskin, D. L., Exacerbation of acetaminophen hepatotoxicity by the anthelmentic drug fenbendazole. Toxicol. Sci. Off. J. Soc. Toxicol. 2012, 125, 607612.
  • 52
    Wakil, S. J., Fatty acid synthase, a proficient multifunctional enzyme. Biochemistry 1989, 28, 45234530.
  • 53
    Witkowski, A., Rangan, V. S., Randhawa, Z. I., Amy, C. M., Smith, S., Structural organization of the multifunctional animal fatty-acid synthase. Eur. J. Biochem./FEBS 1991, 198, 571579.
  • 54
    Wang, W., Lin, R., Zhang, J., Mao, Y. et al., Involvement of fatty acid metabolism in the hepatotoxicity induced by divalproex sodium. Hum. Exp. Toxicol. 2012, 31, 10921101.
  • 55
    Davidson, N. O., Shelness, G. S., Apolipoprotein B: mRNA editing, lipoprotein assembly, and presecretory degradation. Ann. Rev. Nutr. 2000, 20, 169193.
  • 56
    Marsh, J. B., Welty, F. K., Lichtenstein, A. H., Lamon-Fava, S., Schaefer, E. J., Apolipoprotein B metabolism in humans: studies with stable isotope-labeled amino acid precursors. Atherosclerosis 2002, 162, 227244.
  • 57
    Sparks, J. D., Cianci, J., Jokinen, J., Chen, L. S., Sparks, C. E., Interleukin-6 mediates hepatic hypersecretion of apolipoprotein B. Am. J. Physiol. Gastr. Liver Physiol. 2010, 299, G980G989.
  • 58
    Panduro, A., Castrillon, L., Gonzalez, L., Shafritz, D. A., Regulation of hepatic and non-hepatic apolipoprotein A-I and E gene expression during liver regeneration. Biochim. Biophys. Acta 1993, 1167, 3742.
  • 59
    Aldana, L., Gonzalez de Mejia, E., Craigmill, A., Tsutsumi, V. et al., Cypermethrin increases apo A-1 and apo B mRNA but not hyperlipidemia in rats. Toxicol. Lett. 1998, 95, 3139.
  • 60
    Makowski, L., Boord, J. B., Maeda, K., Babaev, V. R. et al., Lack of macrophage fatty-acid-binding protein aP2 protects mice deficient in apolipoprotein E against atherosclerosis. Nat. Med. 2001, 7, 699705.
  • 61
    Miao, W., Hu, L., Scrivens, P. J., Batist, G., Transcriptional regulation of NF-E2 p45-related factor (NRF2) expression by the aryl hydrocarbon receptor-xenobiotic response element signaling pathway: direct cross-talk between phase I and II drug-metabolizing enzymes. J. Biol. Chem. 2005, 280, 2034020348.
  • 62
    Lassen, N., Bateman, J. B., Estey, T., Kuszak, J. R. et al., Multiple and additive functions of ALDH3A1 and ALDH1A1: cataract phenotype and ocular oxidative damage in Aldh3a1(-/-)/Aldh1a1(-/-) knock-out mice. J. Biol. Chem. 2007, 282, 2566825676.
  • 63
    Padda, M. S., Sanchez, M., Akhtar, A. J., Boyer, J. L., Drug-induced cholestasis. Hepatology 2011, 53, 13771387.
  • 64
    Pauli-Magnus, C., Meier, P. J., Hepatobiliary transporters and drug-induced cholestasis. Hepatology 2006, 44, 778787.
  • 65
    Allen, R. M., Marquart, T. J., Albert, C. J., Suchy, F. J. et al., miR-33 controls the expression of biliary transporters, and mediates statin- and diet-induced hepatotoxicity. EMBO Mol. Med. 2012, 4, 882895.
  • 66
    Ashamiss, F., Wierzbicki, Z., Chrzanowska, A., Scibior, D. et al., Clinical significance of arginase after liver transplantation. Ann. Transplant. Quart. Polish Transplant. Soc. 2004, 9, 5860.
  • 67
    Pesce, J. T., Ramalingam, T. R., Mentink-Kane, M. M., Wilson, M. S. et al., Arginase-1-expressing macrophages suppress Th2 cytokine-driven inflammation and fibrosis. PLoS Pathogen. 2009, 5, e1000371.
  • 68
    Wang, Y., Yang, B., Wu, C., Zheng, Z. et al., Plasma and liver proteomic analysis of 3Z-3-[(1H-pyrrol-2-yl)-methylidene]-1-(1-piperidinylmethyl)-1,3–2H-indol-2-one-induced hepatotoxicity in Wistar rats. Proteomics 2010, 10, 29272941.
  • 69
    Lacour, S., Gautier, J. C., Pallardy, M., Roberts, R., Cytokines as potential biomarkers of liver toxicity. Cancer Biomark. 2005, 1, 2939.
  • 70
    Blazka, M. E., Wilmer, J. L., Holladay, S. D., Wilson, R. E., Luster, M. I., Role of proinflammatory cytokines in acetaminophen hepatotoxicity. Toxicol. Appl. Pharmacol. 1995, 133, 4352.
  • 71
    Endres, M., Laufs, U., Huang, Z., Nakamura, T. et al., Stroke protection by 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase inhibitors mediated by endothelial nitric oxide synthase. Proc. Natl. Acad. Sci. USA 1998, 95, 88808885.
  • 72
    Notarnicola, M., Messa, C., Refolo, M. G., Tutino, V. et al., Synergic effect of eicosapentaenoic acid and lovastatin on gene expression of HMGCoA reductase and LDL receptor in cultured HepG2 cells. Lipids Health Dis. 2010, 9, 135143.